G Irwin Gordon Sells 3,000 Shares of Heska Corp. (HSKA) Stock
Heska Corp. (NASDAQ:HSKA) Director G Irwin Gordon sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 29th. The shares were sold at an average price of $66.11, for a total transaction of $198,330.00. Following the completion of the sale, the director now owns 17,596 shares in the company, valued at $1,163,271.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Heska Corp. (NASDAQ:HSKA) traded up 3.19% during mid-day trading on Tuesday, reaching $67.69. 113,084 shares of the company were exchanged. The firm has a market capitalization of $466.93 million, a P/E ratio of 54.20 and a beta of 0.74. Heska Corp. has a 1-year low of $26.25 and a 1-year high of $69.80. The stock has a 50-day moving average of $58.16 and a 200 day moving average of $48.46.
Heska Corp. (NASDAQ:HSKA) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.20. The company had revenue of $33.40 million for the quarter, compared to analyst estimates of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. Heska Corp.’s revenue for the quarter was up 19.3% compared to the same quarter last year. Equities research analysts forecast that Heska Corp. will post $1.32 earnings per share for the current year.
A number of research firms have recently weighed in on HSKA. B. Riley cut shares of Heska Corp. from a “buy” rating to a “neutral” rating and raised their price target for the company from $52.50 to $53.00 in a report on Wednesday, September 21st. Zacks Investment Research cut shares of Heska Corp. from a “buy” rating to a “hold” rating in a report on Thursday, October 20th. Gabelli cut shares of Heska Corp. from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Finally, Benchmark Co. initiated coverage on shares of Heska Corp. in a research note on Tuesday. They issued a “buy” rating and a $78.00 target price for the company. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $66.88.
A number of hedge funds have recently modified their holdings of HSKA. Credit Suisse AG raised its stake in shares of Heska Corp. by 39.8% in the second quarter. Credit Suisse AG now owns 523,982 shares of the company’s stock worth $19,476,000 after buying an additional 149,206 shares during the period. Pembroke Management LTD acquired a new stake in shares of Heska Corp. during the second quarter worth about $5,096,000. Wells Fargo & Company MN raised its stake in shares of Heska Corp. by 4,483.7% in the third quarter. Wells Fargo & Company MN now owns 129,628 shares of the company’s stock worth $7,056,000 after buying an additional 126,800 shares during the period. Emerald Acquisition Ltd. raised its stake in shares of Heska Corp. by 114.5% in the third quarter. Emerald Acquisition Ltd. now owns 146,552 shares of the company’s stock worth $7,976,000 after buying an additional 78,221 shares during the period. Finally, Summit Creek Advisors LLC acquired a new stake in shares of Heska Corp. during the third quarter worth about $4,007,000. Institutional investors own 72.70% of the company’s stock.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related companies with MarketBeat.com's FREE daily email newsletter.